Increased Serum Cathepsin K in Patients with Coronary Artery Disease

PURPOSE: Cathepsin K is a potent collagenase implicated in human and animal atherosclerosis-based vascular remodeling. This study examined the hypothesis that serum CatK is associated with the prevalence of coronary artery disease (CAD). MATERIALS AND METHODS: Between January 2011 and December 2012, 256 consecutive subjects were enrolled from among patients who underwent coronary angiography and percutaneous coronary intervention treatment. A total of 129 age-matched subjects served as controls. RESULTS: The subjects' serum cathepsin K and high sensitive C-reactive protein (hs-CRP) and high-density lipoprotein cholesterol were measured. The patients with CAD had significantly higher serum cathepsin K levels compared to the controls (130.8+/-25.5 ng/mL vs. 86.9+/-25.5 ng/mL, p<0.001), and the patients with acute coronary syndrome had significantly higher serum cathepsin K levels compared to those with stable angina pectoris (137.1+/-26.9 ng/mL vs. 102.6+/-12.9 ng/mL, p<0.001). A linear regression analysis showed that overall, the cathepsin K levels were inversely correlated with the high-density lipoprotein levels (r=-0.29, p<0.01) and positively with hs-CRP levels (r=0.32, p<0.01). Multiple logistic regression analyses shows that cathepsin K levels were independent predictors of CAD (odds ratio, 1.76; 95% confidence interval, 1.12 to 1.56; p<0.01). CONCLUSION: These data indicated that elevated levels of cathepsin K are closely associated with the presence of CAD and that circulating cathepsin K serves a useful biomarker for CAD.

Increased Serum Cathepsin K in Patients with Coronary Artery Disease

PURPOSE: Cathepsin K is a potent collagenase implicated in human and animal atherosclerosis-based vascular remodeling. This study examined the hypothesis that serum CatK is associated with the prevalence of coronary artery disease (CAD). MATERIALS AND METHODS: Between January 2011 and December 2012, 256 consecutive subjects were enrolled from among patients who underwent coronary angiography and percutaneous coronary intervention treatment. A total of 129 age-matched subjects served as controls. RESULTS: The subjects' serum cathepsin K and high sensitive C-reactive protein (hs-CRP) and high-density lipoprotein cholesterol were measured. The patients with CAD had significantly higher serum cathepsin K levels compared to the controls (130.8+/-25.5 ng/mL vs. 86.9+/-25.5 ng/mL, p<0.001), and the patients with acute coronary syndrome had significantly higher serum cathepsin K levels compared to those with stable angina pectoris (137.1+/-26.9 ng/mL vs. 102.6+/-12.9 ng/mL, p<0.001). A linear regression analysis showed that overall, the cathepsin K levels were inversely correlated with the high-density lipoprotein levels (r=-0.29, p<0.01) and positively with hs-CRP levels (r=0.32, p<0.01). Multiple logistic regression analyses shows that cathepsin K levels were independent predictors of CAD (odds ratio, 1.76; 95% confidence interval, 1.12 to 1.56; p<0.01). CONCLUSION: These data indicated that elevated levels of cathepsin K are closely associated with the presence of CAD and that circulating cathepsin K serves a useful biomarker for CAD.

Effect of eicosapentaenoic acid or eicosapentaenoic acid plus carboplatin on proliferation and apoptosis of human lung cancer cell line A-549 / 中华临床营养杂志

Objective To investigate the effects of eicosapentaenoic acid (EPA) or EPA plus carboplatin on the proliferation and apoptosis of human lung cancer cell line A-549.Methods A-549 cells were cultured by 100 μg/ml carboplatin,80 μg/ml EPA,and their combination for 48 hours.MTT assay was used to determine the effect of EPA,carboplatin,or their combination on the proliferation of human lung cancer cell line A-549.The morphological changes of human lung cancer cell line A-549 were observed using HE staining,and apoptosis of A-549 cells was analyzed by flow cytometry.Results MTT assay showed that the proliferation inhibition rate of A-549 cells cultured with EPA plus carboplatin was 85.20％ ± 5.00％,which was significantly higher than that of cells cultured with 80 μg/ml EPA (32.85％ ± 3.00％,P =0.0001 ) or 100 μg/ml carboplatin (53.25％ ±3.00％,P =0.0013 ).HE staining showed apoptosis in all three groups,whereas the apoptosis rate reached 17.05％ ± 4.00％ in the combination group,which was significantly higher than that in carboplatin group (9.49％ ± 1.00％,P =0.0252).Conclusion EPA may enhance the effects of carboplatin in inhibiting the proliferation and promoting the apoptosis of human lung cancer cell line A-549.

Effects of eicosapentaenoic acid combined with etoposide on proliferation and apoptosis of human lung cancer cell line A-549 / 中华临床营养杂志

Objective To study the effects of eicosapentaenoic acid (EPA) combined with etoposide on the proliferation and apoptosis of human lung cancer cell lines A-549 in vitro.Methods The A-549 cells were cultured,respectively,with culture fluids containing 40 μg/ml EPA,10 μg/ml etoposide,40 μg/ml EPA + 10 μg/ml etoposide,20 μg/ml etoposide,or 40 μg/ml EPA + 20 μg/ml.The effects of EPA and/or etoposide on the proliferation of the cell line were detected by MTT assay.The morphological changes of the cells were observed using annexin V-fluorescein isothiocyanate/propidium iodine and acridine orange/ethidium bromide double staining under fluorescence microscope.The apoptosis and the changes of cell cycle were detected by flow cytometry.Results The inhibition rates of EPA plus etoposide groups on the proliferation of human lung cancer cells A-549 were significantly higher than those in other etoposide groups (all P ＜ 0.05).Cell staining showed that the amount of apoptotic cells in EPA plus etoposide groups was significantly larger than that in etoposide groups.The percentages of cells in S and G2/M phases of EPA plus etoposide groups were significantly higher than those of etoposide groups (all P ＜ 0.05).Conclusion EPA may enhance the effect of etoposide on inhibiting proliferation and promoting apoptosis for human lung cancer cells A-549.

Effect of Pharmaceutical Care on the Treatment Outcomes of Epilepsy / 中国药房

OBJECTIVE: To investigate the effect of pharmaceutical care on the treatment outcome of epilepsy and to discuss the necessity for pharmacists' participation in clinical medication and the correlation between the participation of clinical pharmacists and curative effect.METHODS: The epileptic patients treated in our hospital from Jan.2001 to Jan.2007 who accepted serum drug concentration test were included in the study.The treatment outcome data were subjected to statistically analysis.RESULTS & CONCLUSION: The medication guidance provided by pharmacists is highly correlated with the treatment outcome of epilepsy.Reasonable pharmaceutical care provided by pharmacists is much needed in the treatment of epilepsy.